产品
编 号：F624435
分子式：C24H22F2N2O2
分子量：408.44
分子式：C24H22F2N2O2
分子量：408.44
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1346133-11-6
产品详情
生物活性：
LY2444296 is an orally bioavailable, high-affinity and selective short-acting kappa opioid receptor (KOPR) antagonist, with a Ki value of ～1 nM. LY2444296 exhibits anti-anxiety like effects.
体内研究：
LY2444296 displays anti-anxiety like effects in the EPM test.LY2444296 (3 mg/kg; i.p.; 30 min before U69,593 administration) prevents behavioral and neuroendocrine effects caused by the reference kappa agonist U69,593 in cocaine-na?ve rats.LY2444296 reduces anxiety-like and depressive-like behaviors, as well as CORT release, in rats tested after chronic extended access cocaine self-administration, but not in cocaine-na?ve rats.Animal Model:Adult male Sprague Dawley rats (240–250 g)
Dosage:3 mg/kg
Administration:Injected intraperitoneally; 30 min before U69,593 administration
Result:Prevented behavioral and neuroendocrine effects caused by U69,593 in cocaine-na?ve rats.
LY2444296 is an orally bioavailable, high-affinity and selective short-acting kappa opioid receptor (KOPR) antagonist, with a Ki value of ～1 nM. LY2444296 exhibits anti-anxiety like effects.
体内研究：
LY2444296 displays anti-anxiety like effects in the EPM test.LY2444296 (3 mg/kg; i.p.; 30 min before U69,593 administration) prevents behavioral and neuroendocrine effects caused by the reference kappa agonist U69,593 in cocaine-na?ve rats.LY2444296 reduces anxiety-like and depressive-like behaviors, as well as CORT release, in rats tested after chronic extended access cocaine self-administration, but not in cocaine-na?ve rats.Animal Model:Adult male Sprague Dawley rats (240–250 g)
Dosage:3 mg/kg
Administration:Injected intraperitoneally; 30 min before U69,593 administration
Result:Prevented behavioral and neuroendocrine effects caused by U69,593 in cocaine-na?ve rats.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备